Combined treatment of patients with prostatic adenoma and overactive bladder


Cite item

Full Text

Abstract

Of late, we observe a trend to a progressive rise of overactive bladder (OB) morbidity with age. M-cholinolytic drugs are most effective in management of OB but old patients with prostatic adenoma (PA) and comorbid pathology have a risk of acute urinary retention and serious side effects. We have the experience in combined treatment of 30 old patients with PA and OB with M-cholinolytic and alpha-adrenoblocker. The results of the treatment show its efficacy and absence of complications in the control of residual urine for 3 months. Combination of M-cholinolytic with alpha-adreboblocker significantly reduced daily diuresis, improved an accumulation function of the bladder and life quality.

References

  1. Abrams P., Cardozo L., Fall M. The standartisation of terminology of lower urinary tract function. Neurourol. and Urodyn. 2002; 21: 167-178.
  2. Гаджиева Ж. К. Нарушения мочеиспускания: Руководство / Под ред. Ю. Г. Аляева. М.: ГЭОТАР-Медиа; 2010.
  3. Мазо Е. Б., Кривобородов Г. Г. Медикаментозное лечение гиперактивного мочевого пузыря. М.: Вече; 2003.
  4. Hyman M. J., Groutz A., Blaivas J. G. Detrusor instability in men : correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. (Baltimore) 2001; 166: 550-553.
  5. Knutson T., Schafer W., Fall M. et al. Can urodynamic assessment of outflow obstruction predict outcome from waiting? A four year follow up study. Scand. J. Urol. Nephrol. 2001; 35: 463-469.
  6. Greenland I. E., Brading A. F. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J. Urol. (Baltimore) 2001; 165: 245-249.
  7. Harrison S. C., Hunnam G. R., Farrman P. et al. Bladder instability and denervation in patients with bladder outflow obstruction. Br. J. Urol. 1987; 60: 519-524.
  8. Mirone V., Imbimbo C., Sessa G. et al. Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J. Urol. (Baltimore) 2004; 172: 1386- 1392.
  9. Seki N., Karim O. M., Mostwin J. L. Changes in electrical properties of guinea f pig smooth muscle membrane by experimental bladder outflow obstruction. J. Urol. (Baltimore) 1992; 148: 1957-1961.
  10. McConnell J., Abrams P. et al. 6-th International consultation on development in prostate cancer and prostate diseases. Recommendations of the international scientific committee: evaluation and treatment of lower urinary tract symptoms in old men. In: Male lower urinary tract dysfunction evaluation and management. 2006. 21-st edition: 387-401.
  11. Masumori M., Sato Y., Itoh N. Clinical efficacy of naftopidil for benign prostatic hyperplasia the effect on storage symptoms. Jpn. J. Urol. 2004; 7: 335-344.
  12. Kenton K., Lowenstein L., Brubaker L. Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence. Neurourol. and Urodyn. 2010; 29 (4): 555- 557.
  13. Khullar V., Cardozo L., Dmochowski R. Mixed incontinence: curren evidence and future perspectives. Neurourol. and Urodyn. 2010; 29 (4): 618-622.
  14. Khullar V., Hill S., Laval K. U. et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004; 64 (2): 269-274.
  15. Nilvebrant L., Andersson K. E., Gillberg P. G. et al. Tolterodine-a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. 1997; 327 (2-3): 195-207.
  16. Nilvebrant L., Hallen B., Larsson G. Tolterodine-a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997; 60 (13-14): 1129- 1136.
  17. Munding M., Wessells H., Thornberry B. et al. Use of tolterodine in children with dysfunctional voiding: an initial report. J. Urol. (Baltimore) 2001; 165 (3): 926-934.
  18. Soler R. et al. Br. J. Urol. Int. 2010; 106 (2): 287-293.
  19. Peters T. J., Donovan J., Kay H. E. et al. The International Continence Society Benign Prostatic Hyperplasia Study: the bothersomeness of urinary symptoms. J. Urol. (Baltimore) 1997; 157: 885-0889.
  20. Lee J. Y., Kim H. W. et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. Br. J. Urol. Int. 2004; 94: 817-820.
  21. Weiss J. P., Blaivas J. G. Nocturia. Curr. Urol. Rep. 2003; 4: 36.
  22. Jolleys J. V., Donovan J. I., Nanchahal K. et al. Urinary symptoms in the community: how bothersome are they? Br. J. Urol. 1994; 74: 551-555.
  23. Appell R. A., Abrams P. et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. Wld J. Urol. 2001; 19: 141-147.
  24. Steven A., Kaplan et al. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J. Urol. (Baltimore) 2008; 74 (5): S82-S87.
  25. Capple C. R., Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br. J. Urol. 1994; 73: 117-122.
  26. Kyu-Sung Lee, Myuhg-Soo Choo et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J. Urol. (Baltimore) 2005; 174: 1334-1338.
  27. Nishizawa O., Yamaguchi O. et al. Trial of combination treatment with an alpa-blocker plus anticholinergic for BPH with OAB. Neurogen. Bladder Soc. 2009; 20: 288-294.
  28. Голубцова Е. Н., Велиев Е. И. Современные подходы к фармакотерапии гиперактивного мочевого пузыря. Эффект. фармакотер. в урол. 2010; 2: 4-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies